Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that three poster presentations demonstrating the key role of cytokine biology to effectively target both front and back of eye diseases, including clinical data on its lead drug candidate EBI-005 and preclinical data on EBI-029 have been selected for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2014 Annual Meeting taking place May 4-8, 2014, in Orlando, FL.
Help employers find you! Check out all the jobs and post your resume.
